Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Deniz Guranlioglu"'
Autor:
Mohd Kashif Siddiqui, Pragya Shukla, Martin Jenkins, Mario Ouwens, Deniz Guranlioglu, Patrick Darken, Mousumi Biswas
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 13 (2019)
Background: Dual bronchodilation with a long-acting muscarinic antagonist (LAMA)/long-acting β 2 -agonist (LABA) fixed-dose combination (FDC) is an established treatment strategy for chronic obstructive pulmonary disease (COPD). The relative efficac
Externí odkaz:
https://doaj.org/article/21559d8e41ac4dd99629588b5c0f39c8
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease
Bo Ding,1 Lee Kallenbach,2 Lukas Slipski,2 Alan Wilk,2 Dan O’Brien,2 Deniz Guranlioglu3 1AstraZeneca, Gothenburg, Sweden; 2Practice Fusion, San Francisco, CA, USA; 3AstraZeneca, Cambridge, UKCorrespondence: Bo DingAstraZeneca, Pepparedsleden 1, Got
Autor:
Arushi Bamrara, Neda Stjepanovic, Martin Jenkins, John R. Hurst, Mousumi Biswas, Kevin Gruffydd-Jones, Deniz Guranlioglu
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease
John R Hurst,1 Kevin Gruffydd-Jones,2 Mousumi Biswas,3 Deniz Guranlioglu,4 Martin Jenkins,4 Neda Stjepanovic,5 Arushi Bamrara6 1UCL Respiratory, University College London, London, UK; 2GP, Box Surgery, Box, Wiltshire, UK; 3AstraZeneca, Gaithersburg,
Autor:
Shahid Siddiqui, Kacey Rawson, Anthony J. Hickey, Neda Stjepanovic, Omar S. Usmani, Deniz Guranlioglu, Rajiv Dhand
Publikováno v:
3040.e1
Many inhaler devices with varying handling requirements for optimal use are available for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Patients may be prescribed different device types for reliever and maintenance medicat
Autor:
Anthony J. Hickey, K. Rawson, Rajiv Dhand, Omar S. Usmani, Deniz Guranlioglu, Shahid Siddiqui, Neda Stjepanovic
Publikováno v:
B45. COPD: TREATMENT.
Publikováno v:
COPD: therapeutics and trials.
Introduction and objectives Fixed-dose combination (FDC) therapies of long-acting muscarinic antagonists and long-acting β2-agonists (LAMA+LABA) are indicated as maintenance treatment in chronic obstructive pulmonary disease (COPD). This Bayesian ne
Publikováno v:
COPD: therapeutics and trials.
Introduction and objectives To characterize patients with chronic obstructive pulmonary disease (COPD) who were prescribed long-acting muscarinic antagonist/long-acting β2-agonist (LAMA/LABA) fixed-dose combination (FDC) therapy in real-world US-bas
Autor:
M.K. Siddiqui, Mousumi Biswas, Mario Ouwens, Pragya Shukla, Deniz Guranlioglu, Patrick Darken, Martin Jenkins
Publikováno v:
Therapeutic Advances in Respiratory Disease
Background: Dual bronchodilation with a long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) fixed-dose combination (FDC) is an established treatment strategy for chronic obstructive pulmonary disease (COPD). The relative efficacy